Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccinationArticle Published on 2022-11-012022-11-15 Journal: European journal of haematology [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome Adults antibody Antibody Response approved BNT162b2 Cell clinically Combination coronavirus disorder dose Efficacy FDA healthy Hospitalization IgG levels increased mortality Lymphocytes majority mRNA mRNA vaccination mRNA vaccine mRNA-1273 Multiple myeloma NAb NAbs Patient plasma plasma cell disorder. Prospective Study required responses SARS CoV-2 SARS-CoV-2 therapy Treatment vaccination vaccine dose [DOI] 10.1111/ejh.13826 PMC 바로가기
Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replicationArticle Published on 2022-11-012022-11-15 Journal: Journal of biomolecular structure & dynamics [Category] SARS, 치료제, [키워드] added antibiotic antimalarial Antiviral approved binding domain Bruton tyrosine kinase inhibitors China claimed contagious Control country COVID-19 pandemic Dependent disease domain drug drug design FDA in viral in-depth analysis increase Infection inhibiting inhibitor Interaction interfere M pro MD simulation number of infected outbreak Papain Population protease provide Psychological distress quinoline based FDA approved Drugs. RBD Remdesivir Replication required resource RNA RNA dependent RNA polymerase RNA polymerase RNA virus SARS-CoV-2 selected Spike protein spread to target Vaccines viral entry viral replication Virtual screening [DOI] 10.1080/07391102.2021.1913228 PMC 바로가기
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trialArticle Published on 2022-11-012022-11-15 Journal: Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Administered adverse event approved assessment booster booster dose booster vaccination clinical trials Course COVID-19 COVID-19 vaccination COVID-19 vaccine cross-neutralization cross-neutralization. Day double-blind Effect fatigue Heterologous homologous humoral immunogenic immunogenicity incidence injection site pain Local Neutralizing antibodies neutralizing antibody outcome participant Participants Placebo placebo-controlled primary immunogenicity Randomized randomized placebo-controlled trial Recombinant spike protein reported robust Safe Safety safety profile saline placebo SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rate shown SpikoGen subunit the placebo group Trial Vaccine was performed [DOI] 10.1111/imm.13540 PMC 바로가기
An outlook on potential protein targets of COVID-19 as a druggable siteArticle Published on 2022-11-012022-11-15 Journal: Molecular biology reports [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] approved cause claimed clinical trial combating contagious COVID-19 COVID-19 disease Cryo-electron microscopy Delta Efficacy feature genomic help host cell host protein infecting inhibit mechanism of action MERS-CoV Mutation non-structural proteins omicron pandemic Protein Protein target proteolytic cleavage raised Repurposed drug required SARS-CoV SARS-CoV-2 SARS-CoV-2 entry SARS-CoV-2 protein shown similarity spike Spike protein strain suggested the vaccine therapeutic drugs therapeutic interventions Vaccines. variants of SARS-CoV-2 viral infection virus Wuhan X-ray diffraction [DOI] 10.1007/s11033-022-07724-3 PMC 바로가기
Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infectionArticle Published on 2022-11-012022-11-15 Journal: Chemico-biological interactions [Category] SARS, 변종, 치료제, [키워드] ACE2 Analysis angiotensin-converting enzyme 2 Anti-inflammatory anti-inflammatory activity antiviral drug approach approved combating Compound contribute Control COVID-19 COVID-19 infection COVID-19 patients cytokine Efficacy ELIXIR entry of SARS-CoV-2 expression FDA GC-MS group groups hamster hamsters human host in silico in vivo in-silico Infection inhibiting inhibitory effect investigated Lung injury male membrane molecular docking molecular docking studies new SARS-CoV-2 PCR Polyherbal oil Prophylactic Protective real time receptor reduced respiratory diseases SARS-CoV-2 selected significantly Spike protein the SARS-CoV-2 Therapeutics Therapeutics. these compound treat Treatment treatment groups Vaccine variants viral envelope Viral load [DOI] 10.1016/j.cbi.2022.110179 PMC 바로가기
COVID-19: Vaccines and therapeuticsArticle Published on 2022-11-012022-11-16 Journal: Bioorganic & medicinal chemistry letters [Category] SARS, 변종, [키워드] acute respiratory syndrome approved communicable coronavirus Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 therapeutics COVID-19 vaccines death deaths disease effective Health highlight Infection Measures New New variants of SARS-CoV-2 Protective reported Research SARS-CoV-2 SARS-CoV-2. Therapeutic strategies Treatment triggered Vaccine variant virus [DOI] 10.1016/j.bmcl.2022.128987 PMC 바로가기
Miniaturized Real-Time PCR systems for SARS-CoV-2 detection at the Point-of-CareArticle Published on 2022-11-012022-11-15 Journal: Clinica chimica acta; international journal of cli [Category] SARS, 치료기술, [키워드] advance amplification approved detect diagnosis of COVID-19 diagnostic disease disease stage drug feature food gold standard Healthcare system identify Infection lab Lab On Chip limit Molecular biology over PCR POC POC test Point point of care Real-time PCR reduced respiratory SARS-CoV-2 SARS-CoV-2 detection SARS-COV-2 infection sensitivity Spread the United State viral genome Viral infection. Viral load virus [DOI] 10.1016/j.cca.2022.09.014 PMC 바로가기
A precise review on NAATs-based diagnostic assays for COVID-19: A motion in fast POC molecular testsArticle Published on 2022-11-012022-11-15 Journal: European Journal of Clinical Investigation [Category] SARS, 치료기술, [키워드] addressed advance approved assist authorization Care Comparative coronavirus disease COVID-19 diagnostic Diagnostic method disease Emergency expand false-negative global pandemic Health limitation mitigate molecular molecular diagnostic assays molecular test NAAT New nucleic acid amplification nucleic acid amplification techniques parameter platform POC POC testing point-of-care Point-of-care testing. polymerase chain RT-qPCR SARS-CoV-2 Sensitivity and specificity suggested [DOI] 10.1111/eci.13853 PMC 바로가기
Status epilepticus during the COVID-19 pandemic in Cologne, Germany: data from a retrospective, multicentre registryArticle Published on 2022-11-012022-11-16 Journal: Journal of Neurology [Category] COVID19(2023년), SARS, 치료기술, [키워드] aetiology Affect analysed analyses approved caused Characteristics containment measures COVID-19 COVID-19 pandemic COVID-19 patient disease fear Healthcare system hospital Impact impacted In-hospital incidence less management multicentre neurological no infection occurred outcome pandemic Patient patients retrospective SARS-CoV-2 SARS-COV-2 infection Seizure status epilepticus status epilepticus. transfer transmitted Treatment Trial university Variation Vascular [DOI] 10.1007/s00415-022-11260-2 PMC 바로가기
Exploring the anti-SARS-CoV-2 main protease potential of FDA approved marine drugs using integrated machine learning templates as predictive toolsArticle Published on 2022-11-012022-11-15 Journal: International journal of biological macromolecules [Category] SARS, 신약개발, 치료제, [키워드] activity Activity atlas model Activity cliff Algorithm anti-SARS-CoV-2 approved Atla Biological camostat Compound COVID-19 COVID-19 pandemic Cresset data set docked drug drugs effective FDA field Field template FIVE flare group Holichondrin B inactive macromolecules Marine drugs. nafamostat outbreak Predictive protease Protein remained Repurposed drug responsible Safe SARS-CoV-2 Structure structures [DOI] 10.1016/j.ijbiomac.2022.09.086 PMC 바로가기